Vol 55, No 5 (2024)
Review article
Published online: 2024-10-31
Erratum has been published:
#1
Diagnostic and therapeutic challenges of ALK-positive anaplastic large cell lymphoma: case report and literature review
1
, 2, 2, 3, 3, 2, 2, 2
, 2, 2, 3, 3, 2, 2, 2
DOI: 10.5603/ahp.101107
Acta Haematol Pol 2024;55(5):231-237.
Abstract
ALK-positive anaplastic large cell lymphoma (ALCL ALK+) is an extremely rare aggressive T-cell lymphoma that exhibits a chromosomal translocation involving the ALK gene. It accounts for 0.5% of adult lymphomas. We present a case of a 36-year-old female patient admitted to the hospital in poor overall condition with hyperleukocytosis, lymphadenopathy, organomegaly, tachycardia, dyspnea, and overall weakness, diagnosed with ALK-positive ALCL. In the first line of treatment, a standard CHO(E)P (cyclophosphamide, doxorubicin, vincristine, (etoposide), prednisone) chemotherapy was given. In second-line therapy, combining brentuximab vedotin (BV) with conventional chemotherapy resulted in the achievement of complete remission (CR). This paper aims to highlight the challenges in making a definitive diagnosis of ALCL, to emphasize the importance of cytogenetic techniques, and to discuss current treatment options from the literature review.
Keywords: anaplastic large cell lymphomaALK genecytogeneticbrentuximab vedotin
References
- Kaseb H, Mukkamalla S, Rajasurya v. Anaplastic Large Cell Lymphoma. StatPearls. Treasure Island (FL): StatPearls. 2023; [Internet].
- Gromowsky MJ, D'Angelo CR, Lunning MA, et al. ALK-positive anaplastic large cell lymphoma in adults. Fac Rev. 2023; 12: 21.
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–1748.
- Chiattone C, Civallero M, Fischer T, et al. Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project. Hematol Oncol. 2022; 40(5): 953–961.
- Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology. 2020; 52(1): 100–110.
- Falini B, Lazzi S, Pileri S. A comparison of the International Consensus and 5th WHO classifications of T-cell lymphomas and histiocytic/dendritic cell tumours. Br J Haematol. 2023; 203(3): 369–383.
- Martinez-Calle N, Kirkwood AA, Lamb M, et al. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Adv Ther. 2021; 38(7): 3789–3802.
- Chmielowska E. Rzadkie postacie chłoniaków T-komórkowych – aktualne postępowanie. Acta Haematologica Polonica. 2019; 50(3): 103–108.
- Zhang XM, Li YX, Wang WH, et al. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. Eur J Haematol. 2013; 90(3): 195–201.
- Swerdlow W, Campo E, Harris N. classification of tumours of hematopoeietic and lymhoid tissues. Revised 4th edition. IARS, Lyon 2017: 413–418.
- Sibon D, Nguyen DP, Schmitz N, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019; 104(12): e562–e565.
- Guru Murthy GS, Hamadani M, Bhatt VR, et al. Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. Clin Lymphoma Myeloma Leuk. 2017; 17(4): 201–206.
- NCCN Guidelines® Updates: T-Cell Lymphomas. Journal of the National Comprehensive Cancer Network. 2022; 20(3).
- d'Amore F, Gaulard P, Trümper L, et al. ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v108–v115.
- Furqan F, Ahn KW, Chen Y, et al. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. Br J Haematol. 2023; 200(1): 54–63.
- Ishizawa K, Yanai T. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma. Adv Ther. 2019; 36(10): 2679–2696.
- Vu K, Ai W. Update on the Treatment of Anaplastic Large Cell Lymphoma. Curr Hematol Malig Rep. 2018; 13(2): 135–141.
- Schönberger S, van Beekum C, Götz B, et al. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines. J Cell Mol Med. 2018; 22(1): 568–575.
- Lobastova L, Lettau M, Babatz F, et al. CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. Front Cell Dev Biol. 2021; 9: 698503.
- Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017; 130(25): 2709–2717.
- Hsu JC, Jaminion F, Guerini E, et al. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. CPT Pharmacometrics Syst Pharmacol. 2021; 10(11): 1357–1370.
- Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020; 111(12): 4540–4547.
- Tomasini P, Egea J, Souquet-Bressand M, et al. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. Ther Adv Respir Dis. 2019; 13: 1753466619831906.
- Bernabé-Caro R, Garrido P, García-Campelo R, et al. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13: 812–827.
- Greengard E, Mosse YP, Liu X, et al. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol. 2020; 86(6): 829–840.
- Zou Z, Hao X, Zhang C, et al. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. Thorac Cancer. 2022; 13(1): 107–116.
- Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res. 2018; 211: 57–65.
- Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017; 35(28): 3215–3221.
- Balis FM, Thompson PA, Mosse YP, et al. First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol. 2017; 79(1): 181–187.
- Lowe EJ, Reilly AF, Lim MS, et al. Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1. J Clin Oncol. 2023; 41(11): 2043–2053.